VIRPP Stock Overview
Manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Virbac SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €308.25 |
| 52 Week High | €374.00 |
| 52 Week Low | €308.25 |
| Beta | 0.97 |
| 1 Month Change | -5.88% |
| 3 Month Change | -12.24% |
| 1 Year Change | -8.53% |
| 3 Year Change | -15.89% |
| 5 Year Change | 40.11% |
| Change since IPO | 142.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| VIRPP | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -5.9% | 1.7% | 1.6% |
| 1Y | -8.5% | 1.5% | 10.2% |
Return vs Industry: VIRPP underperformed the UK Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: VIRPP underperformed the UK Market which returned 10% over the past year.
Price Volatility
| VIRPP volatility | |
|---|---|
| VIRPP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: VIRPP's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine VIRPP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 5,459 | Habib Ramdani | corporate.virbac.com |
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners.
Virbac SA Fundamentals Summary
| VIRPP fundamental statistics | |
|---|---|
| Market cap | €2.53b |
| Earnings (TTM) | €141.19m |
| Revenue (TTM) | €1.34b |
17.9x
P/E Ratio1.9x
P/S RatioIs VIRPP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRPP income statement (TTM) | |
|---|---|
| Revenue | €1.34b |
| Cost of Revenue | €446.54m |
| Gross Profit | €892.83m |
| Other Expenses | €751.63m |
| Earnings | €141.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 14, 2025
| Earnings per share (EPS) | 16.86 |
| Gross Margin | 66.66% |
| Net Profit Margin | 10.54% |
| Debt/Equity Ratio | 37.2% |
How did VIRPP perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield8%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/24 14:42 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Virbac SA is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laurent Gelebart | BNP Paribas Exane |
| Carole Rozen | CA Cheuvreux |
| Arnaud Cadart | CIC Market Solutions (ESN) |